Article Text

Download PDFPDF
Phase II multicenter open-label study of karenitecin in previously treated epithelial ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study
  1. J. J. KAVANAGH*,
  2. M. W. SILL,
  3. P. T. RAMIREZ*,
  4. D. WARSHAL,
  5. M. L. PEARL§ and
  6. M. A. MORGAN
  1. *Department of Gynecologic Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas;
  2. Department of Gynecologic Oncology, GOG Statistical and Data Center, Buffalo, New York;
  3. Department of Gynecologic Oncology, Cooper Hospital/University Medical Center, Camden, New Jersey;
  4. §Department of Gynecologic Oncology, University of New York at Stony Brook, Stony Brook, New York;
  5. Department of Gynecologic Oncology, University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania
  1. Address correspondence and reprint requests to: John J. Kavanagh, MD, Department of Gynecologic Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 401, Houston, TX 77030, USA. Email: jkavana{at}; and Ms Denise Mackey, Gynecologic Oncology Group, Administrative Office, Four Penn Center, 1600 JFK Boulevard, Suite 1020, Philadelphia, PA 19103, USA.


The topoisomerase I agents are established as a therapy in recurrent ovarian cancer. Karenitecin, an analog of topotecan with solubility and pharmacologic advantages, was tested in a phase II trial in previously treated patients with recurrent or persistent ovarian cancer. The drug was administered intravenously over 1 h at a dose of 1.0 mg/m2 daily for 5 days every 21 days. Patients were treated until disease progression, intolerable toxicity, or voluntary withdrawal. Response was evaluated according to modified RECIST criteria. Twenty-seven patients were entered into the study. One patient was inevaluable for not receiving any treatment. Of the 26 evaluable patients, there were two partial responses and one complete response for a total response rate of 12%. This response rate was insufficient to justify accrual to the second stage. The most common grade 3 or 4 toxicities were neutropenia (19%) and gastrointestinal (15%). Karenitecin is a well-tolerated topoisomerase compound but has minimal activity in extensively pretreated ovarian cancer with the dose-schedule employed.

  • epithelial ovarian cancer
  • karenitecin
  • primary peritoneal cancer

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.